在接受CDK4/6抑制剂治疗的晚期乳腺癌患者中地诺单抗与唑来膦酸的对比分析
Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors.
作者信息
Scafetta Roberta, Donato Marco, Gullotta Carla, Guarino Alessandra, Fiore Cristina, Sisca Luisana, Speziale Elena, Troiano Raffaella, Foderaro Simone, Ricozzi Valentina, Iuliani Michele, Simonetti Sonia, Cavaliere Silvia, Cortellini Alessio, Botticelli Andrea, Scagnoli Simone, Pisegna Simona, Criscitiello Carmen, Pedersini Rebecca, Sposetti Caterina, Tiberi Elisa, D'Auria Giuliana, Vergati Matteo, Mazzotta Marco, Caputo Roberta, Verrazzo Annarita, Rossino Maria Grazia, Domati Federica, Piombino Claudia, Di Lisa Francesca Sofia, Filomeno Lorena, Arcuri Teresa, Puce Federica, Riva Federica, Palleschi Michela, Sirico Marianna, Piras Marta, Stucci Luigia Stefania, De Lisi Delia, Orsaria Paolo, Ippolito Edy, Ramella Sara, Visani Luca, Bertini Niccolò, Bonaparte Ilaria, Gori Stefania, Rossi Luigi, Meattini Icro, Tagliaferri Barbara, Caffo Orazio, Portarena Ilaria, Irelli Azzurra, Cretella Elisabetta, Porta Camillo, Bianchini Giampaolo, Fabbri Agnese, De Giorgi Ugo, Vici Patrizia, Toss Angela, Garrone Ornella, De Laurentiis Michelino, Villa Federica, Berardi Rossana, Minelli Mauro, Vernieri Claudio, Curigliano Giuseppe, Vincenzi Bruno, Tonini Giuseppe, Santini Daniele, Pantano Francesco
机构信息
Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo 200, 00128, Roma, Italy.
Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo 200, 00128, Roma, Italy; Medical Oncology Unit, Central Hospital of Belcolle, Department of Oncology and Hematology, Strada Sammartinese snc, 01100, Viterbo, Italy.
出版信息
Breast. 2025 May 15;82:104502. doi: 10.1016/j.breast.2025.104502.
A comparative analysis of Denosumab (DMAB) and Zoledronic Acid (ZA) was conducted in a real-world cohort of 864 patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer with bone metastases, who were undergoing CDK4/6 inhibitors plus endocrine therapy. We evaluated the time to first skeletal-related events (SREs), progression-free survival (PFS), and overall survival (OS). To adjust for confounding variables, we utilized propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) methodologies. In the unadjusted cohort, ZA was associated with a longer time to first SRE compared to DMAB (HR = 0.77, 95 % CI: 0.61-0.98, p = 0.031). Similar results were obtained in both the PSM (HR = 0.69, 95 % CI: 0.52-0.92, p = 0.011) and IPTW cohorts (HR = 0.74, 95 % CI: 0.63-0.87, p < 0.001), with ZA-treated patients showing an extended time to first SRE compared to those treated with DMAB. No differences in PFS and OS were observed between the two cohorts.
在一个真实世界队列中，对864例激素受体阳性、人表皮生长因子受体2阴性且伴有骨转移的晚期乳腺癌患者进行了地诺单抗（DMAB）和唑来膦酸（ZA）的比较分析，这些患者正在接受CDK4/6抑制剂加内分泌治疗。我们评估了首次发生骨相关事件（SRE）的时间、无进展生存期（PFS）和总生存期（OS）。为了调整混杂变量，我们采用了倾向评分匹配（PSM）和逆概率加权法（IPTW）。在未调整的队列中，与地诺单抗相比，唑来膦酸与首次发生SRE的时间更长相关（HR = 0.77，95%CI：0.61 - 0.98，p = 0.031）。在PSM队列（HR = 0.69，95%CI：0.52 - 0.92，p = 0.011）和IPTW队列（HR = 0.74，95%CI：0.63 - 0.87，p < 0.001）中均获得了类似结果，与接受地诺单抗治疗的患者相比，接受唑来膦酸治疗的患者首次发生SRE的时间延长。两个队列之间未观察到PFS和OS的差异。
Zotero 插件